Split PTAB Denies Pfizer's Challenge To Rituxan Patent
A split U.S. Patent Trial and Appeal Board panel has denied Pfizer Inc.'s request for an inter partes review of a Biogen Inc. patent covering a treatment for Hodgkin's lymphoma, finding...To view the full article, register now.
Already a subscriber? Click here to view full article